BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 14679419)

  • 1. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
    Kiyici M; Gulten M; Gurel S; Nak SG; Dolar E; Savci G; Adim SB; Yerci O; Memik F
    Can J Gastroenterol; 2003 Dec; 17(12):713-8. PubMed ID: 14679419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Georgescu EF; Georgescu M
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.
    Stojakovic T; Putz-Bankuti C; Fauler G; Scharnagl H; Wagner M; Stadlbauer V; Gurakuqi G; Stauber RE; März W; Trauner M
    Hepatology; 2007 Sep; 46(3):776-84. PubMed ID: 17668874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
    Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
    Kimura Y; Hyogo H; Yamagishi S; Takeuchi M; Ishitobi T; Nabeshima Y; Arihiro K; Chayama K
    J Gastroenterol; 2010 Jul; 45(7):750-7. PubMed ID: 20112031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Samy W; Hassanian MA
    Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
    Ozel Coskun BD; Yucesoy M; Gursoy S; Baskol M; Yurci A; Yagbasan A; Doğan S; Baskol G
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):142-9. PubMed ID: 25533429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
    Van Rooyen DM; Gan LT; Yeh MM; Haigh WG; Larter CZ; Ioannou G; Teoh NC; Farrell GC
    J Hepatol; 2013 Jul; 59(1):144-52. PubMed ID: 23500152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
    Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
    Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report].
    Bernal-Reyes R; Escudero RB
    Rev Gastroenterol Mex; 2002; 67(2):70-5. PubMed ID: 12214337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
    Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
    Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin.
    Alfarisi HAH; Ibrahim MB; Mohamed ZBH; Azahari N; Hamdan AHB; Che Mohamad CA
    ScientificWorldJournal; 2020; 2020():4503253. PubMed ID: 33132768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin.
    Gonciarz M; Gonciarz Z; Bielanski W; Mularczyk A; Konturek PC; Brzozowski T; Konturek SJ
    J Physiol Pharmacol; 2010 Dec; 61(6):705-10. PubMed ID: 21224501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
    Ratziu V; de Ledinghen V; Oberti F; Mathurin P; Wartelle-Bladou C; Renou C; Sogni P; Maynard M; Larrey D; Serfaty L; Bonnefont-Rousselot D; Bastard JP; Rivière M; Spénard J;
    J Hepatol; 2011 May; 54(5):1011-9. PubMed ID: 21145828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.